SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLS SELLAS Life Sciences Group Inc.

Post-Mkt 04-15 17:26:57 EDT

1.29

+0.15

+13.16%

盘后1.30

+0.01+0.68%

17:20 EDT

High1.30	Low1.13	Vol1.75M
Open1.14	D1 Closing1.14	Amplitude14.91%
Mkt Cap117.19M	Tradable Cap116.83M	Total Shares90.85M
T/O2.14M	T/O Rate1.93%	Tradable Shares90.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SLS","market":"US","secType":"STK","nameCN":"SELLAS Life Sciences Group Inc.","latestPrice":1.29,"timestamp":1744747200000,"preClose":1.14,"halted":0,"volume":1745173,"hourTrading":{"tag":"盘后","latestPrice":1.2988,"preClose":1.29,"latestTime":"17:20 EDT","volume":6285,"amount":8130.7442325,"timestamp":1744752059895},"delay":0,"floatShares":90562400,"shares":90846692,"eps":-0.504571,"marketStatus":"Post-Mkt","change":0.15,"latestTime":"04-15 17:26:57 EDT","open":1.14,"high":1.3,"low":1.13,"amount":2138589.2690803,"amplitude":0.149123,"askPrice":1.3,"askSize":935,"bidPrice":1.26,"bidSize":5940,"shortable":3,"etf":0,"ttmEps":-0.504571,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1744761600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.14,"preHourTrading":{"tag":"盘前","latestPrice":1.14,"preClose":1.14,"latestTime":"09:16 EDT","volume":11355,"amount":13046.75874,"timestamp":1744722979174},"postHourTrading":{"tag":"盘后","latestPrice":1.2988,"preClose":1.29,"latestTime":"17:20 EDT","volume":6285,"amount":8130.7442325,"timestamp":1744752059895},"volumeRatio":1.618134,"impliedVol":1.4674,"impliedVolPercentile":0.4143},"requestUrl":"/m/hq/s/SLS","defaultTab":"news","newsList":[{"id":"2527365116","title":"Turnium Technology Group Achieves Cross-Selling Milestone with Claratti and SLS Advisory","url":"https://stock-news.laohu8.com/highlight/detail?id=2527365116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527365116?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 01:04","pubTimestamp":1744650268,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Rmr Science Technologies ( ($TSE:TTGI) ). Turnium Technology Group has achieved its first cross-selling success...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turnium-technology-group-achieves-cross-selling-milestone-with-claratti-and-sls-advisory?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turnium-technology-group-achieves-cross-selling-milestone-with-claratti-and-sls-advisory?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2525811315","title":"Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2525811315","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525811315?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 22:44","pubTimestamp":1744123448,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group (SLS) said Tuesday that group three data showed that tambiciclib topped the benchmark for median overall survival in the ongoing phase 2 relapsed/refractory acute myeloid le","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","BK4139","BK7104","SLS.AU"],"gpt_icon":0},{"id":"2525890936","title":"BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml","url":"https://stock-news.laohu8.com/highlight/detail?id=2525890936","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525890936?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 21:27","pubTimestamp":1744118868,"startTime":"0","endTime":"0","summary":"BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R AmlApril 8 (Reuters) - Sellas Life Sciences Group Inc SLS.O:SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2525926258","title":"Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525926258","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525926258?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:50","pubTimestamp":1744116657,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refract...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-announces-os-data-in-cohort-3-from-phase-2-sls009-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-announces-os-data-in-cohort-3-from-phase-2-sls009-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2525989448","title":"Sellas Life Sciences Group Inc:  Overall Response Rate (Orr) of 67% Achieved in Patients With Aml-MRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2525989448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525989448?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:45","pubTimestamp":1744116333,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2525944828","title":"Sellas Life Sciences Group Inc: Trial Continues With Full Data and FDA Regulatory Path Feedback Expected in 1H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525944828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525944828?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:45","pubTimestamp":1744116333,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2525894773","title":"SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2525894773","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525894773?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:45","pubTimestamp":1744116300,"startTime":"0","endTime":"0","summary":"- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing His","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057624/0/en/SELLAS-Announces-Positive-Overall-Survival-in-Cohort-3-from-the-Ongoing-Phase-2-Trial-of-SLS009-in-r-r-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","SLS","BK4139"],"gpt_icon":0},{"id":"2522707530","title":"Nexa Resources Announces 2024 Year-End Mineral Reserves and Mineral Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707530","media":"Newsfile","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707530?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 05:32","pubTimestamp":1743111120,"startTime":"0","endTime":"0","summary":"Commenting on the MRMR update, Ignacio Rosado, CEO of Nexa Resources, stated: \"Our 2024 mineral exploration program focused on near-mine expansion, brownfield and infill drilling, and favorable greenfield projects. At Aripuan, infill drilling at the Babau target defined new Mineral Reserves and increased Inferred Mineral Resources. Through these efforts, we were successful once again this year in replacing and expanding our zinc reserves year-over-year while maintaining a stable mineral resources base, reinforcing the strength and sustainability of our asset portfolio.As a leading polymetallic producer and the fifth largest zinc producer globally, Nexa holds a unique portfolio of operating mines with strong exploration potential and an active pipeline of greenfield projects. In 2025, our mineral exploration program will focus on Mineral Reserves and Mineral Resources expansion near operating mines, along with drilling campaigns on advanced-stage projects.\". Proven and Probable Mineral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nexa-resources-announces-2024-end-213200208.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexa-resources-announces-2024-end-213200208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4168","NEXA","SLS"],"gpt_icon":0},{"id":"2521932496","title":"BRIEF-SELLAS Life Sciences FY Net Income USD -30.881 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521932496","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521932496?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501146,"startTime":"0","endTime":"0","summary":"BRIEF-SELLAS Life Sciences FY Net Income USD -30.881 Million\n\n\nMar 20 (Reuters) - SELLAS Life Sciences FY operating income USD -31.513 million.\n\nFY operating expenses USD 31.513 million\nFY basic EPS USD -0.5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nPLXC69933:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2521049698","title":"Sellas Life Sciences FY Operating Expenses USD 31.513 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521049698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521049698?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nPLXC69933:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","CR","BK4232","LU0985320562.USD","ORR","SLS","LU2463526074.USD","OS","BK4139","ASH","BK4585","BK4161","PR","ODD","INN","NCI","BK4022","BK4218","BK4533","BK4213","BK4107","BK4183","BK4181","LU1699723380.USD","BK4109","ALL","LU2355687059.USD","BK4588","R","BK4202","BK4097"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","LPTX","PL","OUST","JEF","BBNX","DRI","ASO","CBUS","MLKN","FBRX","RLMD","ACRV","COYA","TELA","SLS","LVTX","THRD","SKYE","WOR","BRAG","GDEV","SPRY","ALUR","MBRX","MGNX","TH","RUM","BCAB","CURV","LEN","SOWG","TITN","SBS","CDLR","NKTX","BLRX","KLC","PAYX","CELC","CMC","FLUX","MREO","JKS","DERM","MNSO","BRNS","NKE"],"gpt_icon":1},{"id":"2520008973","title":"The Smartest Growth Stock to Buy With $1,000 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2520008973","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520008973?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 15:55","pubTimestamp":1742370900,"startTime":"0","endTime":"0","summary":"Plenty of volatility awaits, but this market's potential growth is enormous thanks to cost-effective technological leaps.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/19/the-smartest-growth-stock-to-buy-with-1000-right-n/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2517231910","title":"Tom's of Maine Introduces Whiten+ Toothpaste: Natural, Effective Whitening","url":"https://stock-news.laohu8.com/highlight/detail?id=2517231910","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517231910?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 22:30","pubTimestamp":1741185000,"startTime":"0","endTime":"0","summary":"KENNEBUNK, Maine, March 5, 2025 /PRNewswire/ -- Tom's of Maine, a certified B Corp and leader in natural and effective personal care, proudly announces the launch of Tom's of Maine Whiten+ Toothpaste.This innovative whitening solution combines naturally derived mineral technology and plant-based cleansers to remove 95% of surface stains in just two weeks with twice-daily brushing.Available in two formulas — Whiten+ Deep Clean  in Peppermint and Spearmint, and Whiten+ Coconut Oil in Gentle Mint — Whiten+ is specifically formulated for those who want a natural, effective whitening toothpaste.\"At Tom's of Maine, our commitment to people and the planet has guided us for over 50 years,\" said Cristiane Martini, General Manager at Tom's of Maine. \"That's why we're excited to introduce Whiten+. Rooted in nature and backed by science, this whitening toothpaste delivers results, while staying true to what matters most to our consumers: naturally sourced and derived ingredients without artificial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/toms-maine-introduces-whiten-toothpaste-143000623.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/toms-maine-introduces-whiten-toothpaste-143000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985320562.USD","LU1430594728.SGD","LU2108987350.USD","LU1941712264.USD","LU1236620834.HKD","LU2463526074.USD","LU0323591593.USD","LU0731783394.SGD","LU1150488135.SGD","LU1599440770.SGD","BK4532","BK4585","BK4018","LU1675838814.USD","LU1150488218.USD","BK4504","LU1236620750.USD","SLS","LU0266013472.USD","BK4533","LU2125154778.USD","CL","BK4588","LU2360032135.SGD","SG9999001440.SGD","BK4139","LU1585245621.USD","LU2125154935.USD","LU1941712348.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2513732153","title":"NASA May Cancel Boeing's Big $82 Billion Space Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2513732153","media":"Motley Fool","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513732153?lang=en_us&edition=full_marsco","pubTime":"2025-02-23 19:07","pubTimestamp":1740308820,"startTime":"0","endTime":"0","summary":"The aerospace giant's loss may be other companies' gain, with SpaceX and Blue Origin among the prime potential beneficiaries.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/23/nasa-may-cancel-boeings-big-82-billion-space-oppor/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4516","LU1435385759.SGD","BA","BK4551","SLS","LU2326559502.SGD","BK4585","BK4139","BK4187","BK4564","BK4588","LU1429558221.USD"],"gpt_icon":1},{"id":"2513627963","title":"Blue Origin Prepares for Layoffs. Here's What Space Stock Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2513627963","media":"Motley Fool","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513627963?lang=en_us&edition=full_marsco","pubTime":"2025-02-22 19:07","pubTimestamp":1740222420,"startTime":"0","endTime":"0","summary":"When it comes to space companies, layoffs aren't always bad news.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/22/blue-origin-prepares-for-layoffs-heres-what-space/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4564","BK4139","BK4551","BK4211","BK4187","BA","BK4516","LU1429558221.USD","BK4585","LU1435385759.SGD","BK4588","ISBC","SLS","LU2326559502.SGD"],"gpt_icon":1},{"id":"2510245830","title":"Boeing to Cut 400 Jobs on NASA's SLS Moon Rocket Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2510245830","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510245830?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 19:10","pubTimestamp":1739185829,"startTime":"0","endTime":"0","summary":"Boeing  plans to eliminate around 400 positions on NASA's Space Launch System moon rocket program by April, multiple news outlets reported Saturday, citing an email from a Boeing spokesperson.The layoffs are reportedly tied to changes in NASA's Artemis project and cost estimates, with Boeing working to move affected employees to other operations within the company.The job cuts total one-third of the workforce assigned to the SLS project, which has faced delays, cost overruns, and technical challenges, according to media reports.NASA said the SLS rocket remains a key part of its Artemis campaign, which aims to return humans to the moon and eventually reach Mars, news outlets reported.Boeing did not immediately respond to MT Newswires' request for comment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b0f18af0df2403a7def13b0da33f9af8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","LU2326559502.SGD","BK4588","BK4187","BA","BK4516","BK4585","LU1429558221.USD","LU1435385759.SGD","BK4551","BK4564","BK4139"],"gpt_icon":1},{"id":"2508143109","title":"Largest borrow rate increases among liquid names","url":"https://stock-news.laohu8.com/highlight/detail?id=2508143109","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508143109?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 21:45","pubTimestamp":1738590316,"startTime":"0","endTime":"0","summary":"Latest data shows the largest indicative borrow rate increases among liquid option names include: Sellas Life Sciences (SLS) 69.57% +2.56, Cardinal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/largest-borrow-rate-increases-among-liquid-names-523?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/largest-borrow-rate-increases-among-liquid-names-523?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2507034528","title":"Sellas $25M registered direct offering priced at $1.27 per share and warrant","url":"https://stock-news.laohu8.com/highlight/detail?id=2507034528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507034528?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 04:15","pubTimestamp":1738095313,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences (SLS) announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-25m-registered-direct-offering-priced-at-1-27-per-share-and-warrant?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-25m-registered-direct-offering-priced-at-1-27-per-share-and-warrant?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2507528189","title":"Sellas Life Sciences Group Announces $25 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2507528189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507528189?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 04:11","pubTimestamp":1738095071,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUA328QKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sellaslifesciences.com","stockEarnings":[{"period":"1week","weight":0.0962},{"period":"1month","weight":0},{"period":"3month","weight":0.2278},{"period":"6month","weight":-0.088},{"period":"1year","weight":-0.1493},{"period":"ytd","weight":0.0962}],"compareEarnings":[{"period":"1week","weight":0.0689},{"period":"1month","weight":-0.0421},{"period":"3month","weight":-0.074},{"period":"6month","weight":-0.0742},{"period":"1year","weight":0.0553},{"period":"ytd","weight":-0.0801}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.033421},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.042394},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.053487},{"month":4,"riseRate":0.454545,"avgChangeRate":0.056599},{"month":5,"riseRate":0.7,"avgChangeRate":0.120128},{"month":6,"riseRate":0.2,"avgChangeRate":-0.246701},{"month":7,"riseRate":0.4,"avgChangeRate":-0.008929},{"month":8,"riseRate":0.3,"avgChangeRate":-0.085169},{"month":9,"riseRate":0.3,"avgChangeRate":-0.018863},{"month":10,"riseRate":0.3,"avgChangeRate":0.043213},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.057526},{"month":12,"riseRate":0.181818,"avgChangeRate":-0.069398}],"exchange":"NASDAQ","name":"SELLAS Life Sciences Group Inc.","nameEN":"SELLAS Life Sciences Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SELLAS Life Sciences Group Inc.,SLS,SELLAS Life Sciences Group Inc.股票,SELLAS Life Sciences Group Inc.股票老虎,SELLAS Life Sciences Group Inc.股票老虎国际,SELLAS Life Sciences Group Inc.行情,SELLAS Life Sciences Group Inc.股票行情,SELLAS Life Sciences Group Inc.股价,SELLAS Life Sciences Group Inc.股市,SELLAS Life Sciences Group Inc.股票价格,SELLAS Life Sciences Group Inc.股票交易,SELLAS Life Sciences Group Inc.股票购买,SELLAS Life Sciences Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}